FIELD: pharmacology.
SUBSTANCE: invention relates to pharmacology, namely to a solution having antiviral activity against tick-borne encephalitis. Solution, having antiviral activity against tick-borne encephalitis, is characterized by fact that, it is an exopolysaccharide obtained from marine bacteria Pseudoalteromonas nigrifaciens stock KMM 156.
EFFECT: above described solution allows to correct the immunodeficient disease of a body induced by tick-borne encephalitis virus.
1 cl, 2 tbl
Title | Year | Author | Number |
---|---|---|---|
GAMMA INTERFERON INDUCTOR | 2014 |
|
RU2564011C1 |
AGENT POSSESSING ANTIVIRAL ACTION AGAINST TICK-BORNE ENCEPHALITIS VIRUSES AND HERPES SIMPLEX TYPE I | 2018 |
|
RU2697887C1 |
ANTIVIRAL COMPOSITION | 2018 |
|
RU2697886C1 |
ANTIVIRAL AGENT AGAINST TICK-BORNE ENCEPHALITIS VIRUS | 2022 |
|
RU2812292C1 |
ANTIVIRAL AGENT AGAINST TICK-BORNE ENCEPHALITIS VIRUS | 2022 |
|
RU2809094C1 |
METHOD FOR EVALUATING DEGREE OF VIRAL CYTOPATHOGENICITY | 2011 |
|
RU2466190C1 |
1-PHENYL-3-OXY-4-ETOXYCARBONYL-5-N-BROMOPHENYL-2,5-DIHYDROPYRROLE-2-ON POSSESSING ANTIVIRUS ACTIVITY | 1988 |
|
SU1573813A1 |
LINE OF DUPLEX FIBROBLAST CELLS OF EASY HUMAN EMBRYO FOR ALLOCATION, IDENTIFICATIONS OF VIRUSES AND OBTAINING OF DIAGNOSTIC AND VACCINAL PREPARATIONS | 2006 |
|
RU2343194C2 |
ANTIVIRAL AGENT AGAINST HERPES SIMPLEX VIRUS TYPE 1 | 2022 |
|
RU2782935C1 |
ADJUVANT FOR ANTI-VIRAL VACCINES | 2017 |
|
RU2676266C2 |
Authors
Dates
2018-04-23—Published
2016-06-28—Filed